检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:麻尔孜雅·米吉提 巴哈尔古丽·赛依提 Marziya mijiti;Baharguri sayti(Children’s ophthalmology Department of Urumqi eye,ear,nose and throat hospital Urumqi,Xinjiang 830002,China)
机构地区:[1]乌鲁木齐市眼耳鼻喉专科医院儿童眼科,新疆乌鲁木齐830002
出 处:《中国医学文摘(耳鼻咽喉科学)》2021年第4期69-70,73,共3页Chinese Medical Digest(Otorhinolaryngology)
摘 要:目的探究泪道探通术联合人工鼻泪管植入术治疗慢性泪囊炎的临床效果。方法 2018年6月~2020年6月,进行慢性泪囊炎治疗探究,样本源自本院收治的此疾病患者,随机选取并1~60编号,抽签平分为对照组、试验组,分别给予泪道探通术、泪道探通术联合人工鼻泪管植入术,比较治疗效果,评估安全性。结果试验组治疗总有效率高于对照组,P<0.05;试验组并发症率低于对照组,P<0.05。结论在慢性泪囊炎治疗中,泪道探通术联合人工鼻泪管植入术治疗效果突出,且安全性较高,值得推广。Objective To explore the clinical effect of lacrimal passage exploration combined with artificial nasolacrimal tube implantation in the treatment of chronic dacryocystitis. Methods From June 2018 to June 2020, the treatment of chronic dacryocystitis was explored. Samples were collected from patients with this disease admitted to this hospital. They were randomly selected and numbered from 1 to 60, and they were divided into the control group and the test group by lottery. Lacrimal passage probing surgery, lacrimal passage probing surgery combined with artificial nasolacrimal tube implantation were used to compare the therapeutic effects and evaluate the safety. Results: The total effective rate of treatment in the experimental group was higher than that in the control group, P<0.05;the complication rate in the experimental group was lower than that in the control group, P<0.05. Results The total effective rate of treatment in the experimental group was higher than that in the control group, P<0.05;the complication rate in the experimental group was lower than that in the control group, P<0.05. Conclusion Lacrimal passage probing combined with artificial nasolacrimal tube implantation is effective and safe in the treatment of chronic dacryocystitis.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:18.222.110.185